{
    "clinical_study": {
        "@rank": "53611", 
        "arm_group": [
            {
                "arm_group_label": "Low dose, insulin degludec", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Medium dose, insulin degludec", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "High dose, insulin degludec", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IDegAsp 50", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to investigate safety,\n      tolerability and pharmacokinetic (the exposure of the trial drug in the body) and\n      pharmacodynamic (the effect of the investigated drug on the body) characteristics of insulin\n      degludec (insulin 454) and insulin degludec/insulin aspart (IDegAsp) 50 - formerly SIAM),\n      both explorative formulations, not similar to the proposed commercial formulation, in\n      healthy male Japanese subjects."
        }, 
        "brief_title": "Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects", 
        "completion_date": {
            "#text": "March 2007", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Healthy"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japanese passport holder\n\n          -  Japanese-born parents\n\n          -  Body mass index (BMI) between 18.0 and 27.0 kg/m^2 (both inclusive)\n\n          -  Fasting blood glucose of below or equal to 6 mmol/L\n\n          -  Healthy male subjects, who are considered to be generally healthy based on an\n             assessment of medical history, physical examination and clinical laboratory data at\n             screening, as assessment of medical history, physical exjudged by the Investigator\n\n        Exclusion Criteria:\n\n          -  The receipt of any investigational drug within 3 months prior to this trial\n\n          -  Subjects with a history of significant multiple drug allergies or with a known\n             allergy to the trialproduct or any medicine chemically related to the trial product,\n             as judged by the Investigator"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865331", 
            "org_study_id": "NN5401-1788", 
            "secondary_id": "2006-002615-26"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Low dose, insulin degludec", 
                    "Medium dose, insulin degludec", 
                    "High dose, insulin degludec"
                ], 
                "description": "Single dose administered subcutaneously (s.c., under the skin).", 
                "intervention_name": "insulin degludec", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Low dose, insulin degludec", 
                    "Medium dose, insulin degludec", 
                    "High dose, insulin degludec", 
                    "IDegAsp 50"
                ], 
                "description": "Administered subcutaneously (s.c., under the skin)", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDegAsp 50", 
                "description": "Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)", 
                "intervention_name": "insulin degludec/insulin aspart 50", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 27, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled, Single-dose, Parallel Group Trial With Insulin 454 and SIAM 50 in Healthy Male Japanese Subjects", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Hanne Haahr", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Frequency of adverse events (AEs)", 
            "safety_issue": "No", 
            "time_frame": "From dosing visit and until follow-up 7-21 days after last dosing visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865331"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the serum insulin concentration curve", 
                "safety_issue": "No", 
                "time_frame": "0-96 hours after dosing"
            }, 
            {
                "measure": "Area under the glucose infusion rate curve", 
                "safety_issue": "No", 
                "time_frame": "0-24 hours after dosing"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}